Glucocorticoids affect glucose metabolism in adults and fetuses, but their effects on materno-47 fetal glucose partitioning remain unknown. This study measured maternal hepatic glucose 48 handling and placental glucose transport together with insulin signalling in these tissues in 49 mice drinking corticosterone either from day (D) 11 to D16 or D14 to D19 of pregnancy 50 (term=D21). On the final day of administration, corticosterone-treated mice were 51 hyperinsulinaemic (P<0.05) but normoglycaemic compared to untreated controls. In maternal 52 liver, there was no change in glycogen content or glucose-6-phosphatase activity but 53 increased Slc2a2 glucose transporter expression in corticosterone-treated mice, on D16 only 54 (P<0.05). On D19, but not D16, transplacental 3 H-methyl-D-glucose clearance was reduced 55 by 33% in corticosterone-treated dams (P<0.05). However, when corticosterone-treated 56 animals were pair-fed to control intake, to prevent the corticosterone-induced increase in food 57 GLUT, glucose transporter; GSK-3β, glycogen synthase kinase 3β; IGF1R, insulin-like 72 growth factor type I receptor; IR, insulin receptor; mTOR, mechanistic target of rapamycin; 73 p70 S6 kinase, p70 ribosomal protein S6 kinase; PF, pair-fed 74
INTRODUCTION 75
Glucocorticoids have an important role in regulating metabolism in adult animals (McMahon 76
MATERIALS AND METHODS 161

Animals 162
All procedures were conducted under the Animals (Scientific Procedures) Act 1986. 163 C57BL6/J mice were group housed, in 12 hr:12 hr light:dark conditions with ad libitum 164 access to water and standard chow (Rat and Mouse Number 3 Breeding, Special Diet 165 Services). Female mice (6-8 weeks old) were mated overnight with stud males and the day of 166 copulatory plug detection designated day (D) 1 of pregnancy. As described in detail 167 previously (Vaughan et al., 2012) , pregnant females were randomly allocated to receive 168 corticosterone treatment (corticosterone 21-hemisuccinate, Q1562-000, Steraloids Inc, 169
Newport, RI, USA; 200 µg ml -1 in drinking water) either from D11 to D16 (n=20) or from 170 D14 to D19 (n=31) (Fig. 1 ). Mean corticosterone dose was 83 ± 9 µg g -1 day -1 in dams treated 171 from D11 to D16 and 81 ± 6 µg g -1 day -1 in those treated later in pregnancy. Controls (n=74) 172 drank tap water throughout. Daily ad libitum food intake per mouse was significantly greater 173
than control values during corticosterone treatment from D14 to D19 (5.2 ± 0.1 g day -1 , n=4 174 cages; controls 4.3 ± 0.1 g day -1 , n=8 cages, P<0.05), but not D11 to D16 (4.3 ± 0.1 g day -1 , 175 n=6 cages; controls 4.1 ± 0.2 g day -1 , n=15 cages) (Vaughan et al., 2012) . Consequently, a 176 subset of animals (n=14) were corticosterone treated and limited to the average food intake of 177 control mice between D14 and D19. Mice were studied on D16 or D19, according to the 178 methods detailed below. 179 180
Materno-fetal 3 H-methyl-D-glucose clearance and tissue collection 181
On the study day, all mice were anaesthetized with an intraperitoneal injection of fentanyl-182 fluanisone and midazolam in water (1:1:2, 10 µg ml-1, Janssen Animal Health, High 183 Wycombe, UK). In a subset of animals (n=41), unidirectional materno-fetal clearance of the 184 non-metabolisable analogue, 3 H-methyl-D-glucose (MeG, NET379001MC, specific activity 185 2.22 TBq mmol -1 ) was measured at both ages using previously described techniques (Sibley 186 et al., 2004) . In all mice, a blood sample was taken from the heart into a chilled, EDTA-187 coated tube. The mouse was then killed by cervical dislocation and weighed before and after 188 removal of the uterus. The maternal liver and individual placentae were dissected out, 189 weighed and flash frozen in liquid nitrogen. Blood samples were centrifuged and the 190 separated plasma stored at -20°C. In animals given MeG, the time (<4 min) from injection of 191 the tracer to collection of the blood sample was recorded and MeG content was measured in 192 maternal plasma and in whole fetuses digested in Biosol (National Diagnostics, Hull, UK)using liquid scintillation counting (Optiphase Hisafe and LKB Wallac 1216 Rackbeta, both 194 Perkin Elmer, Cambridge, UK). 195
Blood glucose and plasma hormone measurements 196
Glucose concentration was measured in whole blood at the time of collection using a hand-197 held glucometer (One-Touch, Orthoclinical Diagnostics, High Wycombe, UK). 198
Corticosterone, insulin, and insulin-like growth factor I (IGF-I) concentrations were 199 measured in EDTA-plasma. 200
Corticosterone was measured using a commercially available radioimmunoassay (#07-201 120102, MP Biomedicals, Orangeburg, NY, USA) as described previously (Vaughan et al., 202 2012 ). Intra-assay and interassay coefficients of variation for three pools of quality controls 203 were 7.3% (mean 193.9 ng ml -1 ) and 6.9% (mean 248.7 ng nl -1 ), respectively, and the lower 204 detection limit of the assay was 7.7 ng ml -1 . Rodent-specific enzyme-linked immunosorbent 205 assays (ELISA) were used to measure insulin (Crystal Chem Inc, Downers Grove, IL, USA) 206
and IGF-I (R&D Systems Europe Ltd, Abingdon, UK). In all cases, intra-assay coefficient of 207 variation was less than 7%. The limits of detection of the assays were 0.1 ng ml -1 for insulin 208 and 3.5 pg ml -1 for IGF-I. 209
210
Glycogen and protein content, and glucose-6-phosphatase activity 211
Glycogen content and glucose-6-phosphatase activity were determined per gram of maternal 212 liver (n=5-8 per treatment group), as described previously (Franko et al., 2007) . Briefly, for 213 the determination of glycogen, liver homogenates in ice-cold water (0.1ml of 100 mg/ml 214 homogenate, in duplicate) were incubated with amyloglucosidase (70U) for 10 minutes. 215 Subsequently, the reaction mixture was deproteinised (zinc sulphate and barium hydroxide) 216 and centrifuged before glucose concentration was measured in the supernatant using a Yellow 217
Springs glucose analyser (2300 Statplus) (Franko et al., 2007) . For the determination of 218 glucose-6-phosphatase activity, homogenates made in 250 µM sucrose solution (0.1ml of 10 219 mg/ml homogenate) were incubated with glucose-6-phosphate (25 µM) for 10 minutes. The 220 reaction was stopped by the addition of trichloracetic acid-ascorbic acid solution and then 221 centrifuged. Inorganic phosphate was determined colorimetrically in the supernatant through 222 the addition of ammonium molybdate, in the presence of arsenite-citrate reagent (Fowden et 223 al., 1993) . For both assays, non-enzymatic production of glucose or phosphate wasdetermined for each homogenate and subtracted from the enzymatic production. Liver and 225 placenta protein content was determined using the Lowry assay (Forhead et al., 2003) . 226
227
Signalling protein abundance and phosphorylation 228
Western blotting was used to determine the total abundance and phosphorylation level of 229 signalling proteins both in maternal liver and placentae (n=5-9 per group, one placenta per 230 litter). Protein extracts were resolved by electrophoresis and transferred to a nitrocellulose 231 membrane for interrogation. Equal protein loading was verified by Ponceau staining 232 (Romero-Calvo et al., 2010). Antibodies to the following targets were used: insulin receptor 233 β, IGF-I receptor β (both 1:400 dilution, from Santa Cruz Biotechnology, Inc. Dallas, TX, 234 USA), Akt total and phosphorylated (Ser473), glycogen synthase kinase 3β total and 235 phosphorylated (Ser21/9), 4E-binding protein total and phosphorylated (Thr37/46), and p70 236 S6 kinase total and phosphorylated (Thr389) (all 1:1000 dilution, from Cell Signalling 237
Technology, Danvers, MA, USA). The intensity of antibody binding was visualised using the 238 enhanced chemiluminescence reaction (Amersham) and quantified with Image J. 239
Gene expression 240
Quantitative real time PCR was used to measure gene expression in maternal liver and in the 241 placenta second closest in weight to the mean of each litter (n=6 per treatment, per age). 242
Expression of Slc2a1 (Taqman gene expression assay Mm00441473_m1). Slc2a2 243 Corticosterone treatment from D11 to D16 reduced the weight of the pregnant mouse on D16 271 (Table 2) . Specifically, the gravid uterus was lighter in corticosterone-treated animals 272 whereas maternal carcass weight did not differ significantly, compared to controls (Table 2) . 273
When corticosterone was given from D14 to D19, there was no effect of treatment on either 274 total body weight, uterus weight or carcass weight on D19, even when corticosterone treated 275 mice were pair-fed to controls (Table 2) . However, when weights were expressed as a 276 percentage of whole body weight, there was an overall increase in the percentage weight of 277 maternal carcass and decrease in percentage weight of the uterus following corticosterone 278 administration at both D16 and D19 (Table 2) . 279
Corticosterone reduced fetal weight by 8% and 19% at D16 and D19, respectively (Table 2) . 280
Placental weight was also reduced by corticosterone treatment at both ages, regardless of 281 maternal food intake ( Table 2 ). The number of viable fetuses per litter was unaffected by 282 maternal treatment (Table 2) . 283
Maternal liver 284
Glucogenic capacity 285
Following corticosterone administration from D11 to D16, the maternal liver was lighter as a 286 percentage of carcass weight, although not as an absolute value compared to controls (Table  287 3). At D19, neither absolute nor percentage liver weight was affected by corticosterone 288 treatment. Neither hepatic glycogen content nor glucose-6-phosphatase activity were affected 289 by treatment at either age. However, there was a significant decrease in hepatic protein 290 content in D14-19 corticosterone-treated, pair fed animals, relative to those receiving 291 corticosterone and eating ad libitum (Table 3) . 292
Gene expression 293
Hepatic Slc2a1 glucose transporter expression was significantly lower than controls in 294 animals given corticosterone from D14 to D19 but not from D11 to D16 (Fig 2) . Conversely, 295
Slc2a2 expression was significantly elevated in animals given corticosterone from D11 to 296 D16 but not from D14 to D19 (Fig. 2) . Abundance of the Nr3c1 glucocorticoid receptor in the 297 liver of the pregnant mouse was reduced by glucocorticoid treatment at both gestational ages 298 (Fig. 2) . Furthermore, corticosterone-treated animals had a significantly lower hepatic 299 expression of the glucocorticoid-activating Hsd1 gene, compared to controls, at D16 but not 300 at D19. Hsd2 abundance was too low to quantify accurately in liver tissue. Hepatic 301 expression of the Redd1 gene was increased ~4-fold in ad libitum fed, corticosterone-treated 302 dams at both D16 and D19 but was not different from controls in corticosterone treated, pair-303 fed animals at D19 (Fig. 2) . 304
Signalling protein abundance and phosphorylation 305
Corticosterone treatment did not significantly alter hepatic expression of the insulin receptor 306 β or the insulin-like growth factor type I receptor β, compared to controls at either age (Fig.  307 3). Downstream of the receptors, total Akt but not serine-473 phosphorylated Akt was 308 reduced by corticosterone treatment at D16 (Fig. 3) . In contrast, phosphorylated but not total 309
Akt was increased in the corticosterone-treated, pair-fed group. The ratio of phospho to total 310
Akt was increased in all corticosterone treated groups, irrespective of age or food intake 311 during treatment. Serine-9/21 phosphorylated GSK-3β was also increased during 312 corticosterone treatment at both ages, regardless of maternal food intake. Total GSK-3β 313 abundance was affected by treatment on D19 only, when it was higher in the corticosterone-314 treated, ad libitum fed group than in either the corticosterone-treated, pair-fed animals or the 315 untreated controls. Although neither total nor phosphorylated 4E-BP1 were affected by 316 corticosterone, there was a significant effect of treatment on the phosphorylation of p70 S6 317 kinase at threonine-389 on D19, which was again highest in the D14 to D19 treated, ad 318 libitum fed group. 319
Placenta 320
Materno-fetal MeG clearance 321
There was an overall effect of treatment on transplacental methyl-D-glucose clearance at D19 322 (P=0.04), but not D16 (P>0.05, Fig. 4 ). Compared to D19 controls, both materno-fetal 323
clearance and fetal accumulation of the tracer was lower in those mice given corticosterone 324 from D14 to D19 (Fig. 4) . However, limiting food intake to control levels in corticosterone-325 treated dams abolished the effect on placental glucose transport at D19. 326
Gene expression 327
Placental expression of both glucose transporter genes, Slc2a1 and Slc2a3 was increased in 328 corticosterone treated mice on D16 (Fig. 5) . However, on D19 Slc2a1 and Slc2a3 expression 329 was similar in all groups. Conversely, placental Redd1 expression was increased in ad libitum 330 fed, corticosterone treated dams on D19 but not D16. Pair-feeding corticosterone-treated 331 dams between D14 and D19 limited the increase in Redd1 expression in the placenta such 332 that there was no significant difference from control values (Fig. 5) . The growth factor Vegf 333 was more highly expressed in the placenta after corticosterone treatment only on D19. There 334 was no change in Igf2 or Igf2P0 expression with corticosterone treatment at either age (Fig.  335 5). Moreover, there was no significant difference in placental expression of Nr3c1, Hsd1 and 336
Hsd2 between control and corticosterone-treated animals, as reported previously (Vaughan et 337 al., 2012) . 338
Signalling protein abundance and phosphorylation 339
Placental insulin receptor and IGF-I receptor expression levels did not differ with maternal 340 treatment at either D16 or D19 (Fig. 6 ). On D16 corticosterone significantly reduced 341 phosphorylation of Akt at the serine-473 residue, although total protein abundance was 342 similar to controls. Total Akt abundance was lower in corticosterone-treated, pair-fed animals 343
in particular compared to controls at D19, but the phospho form was not affected by 344 treatment. Neither total expression nor phosphorylation of GSK-3β in the placenta was 345 altered by corticosterone at either age (Fig. 6 ). There was no change in abundance or 346 phosphorylation of 4E-BP1 or p70 S6 kinase at D16. However, on D19 there was a tendency 347 for corticosterone treatment to increase total 4E-BP1 abundance, irrespective of food intake, 348 without affecting abundance of the threonine-37/46 phosphorylated form. Consequently, 349
there was a significant decrease in the phospho-4E-BP1:total 4E-BP1 ratio on D19 (P=0.048, 350 This study is the first to demonstrate that in vivo placental glucose transport is reduced in 358 mice given exogenous corticosterone in late pregnancy. Plasma insulin concentration and 359 hepatic insulin signalling were elevated in corticosterone treated dams but there was no effect 360 on maternal hepatic glucogenic capacity or blood glucose concentration. Contrastingly, 361 depending upon the timing of corticosterone administration, there were alterations in 362 placental Akt-mTOR signalling consistent with reduced protein synthesis and the observed 363 placental growth restriction. Although the precise physiological changes in the mother and 364 placenta depended upon maternal food intake, ultimately maternal glucocorticoid excess led 365 to a reduction in feto-placental growth. 366
When pregnant mice were given exogenous corticosterone in their drinking water, plasma 367 corticosterone concentrations were significantly higher in dams fed ad libitum compared to 368 those restricted to control food intake, even though the total amount of corticosterone drunk preferential decrease in weight of the uterus and contents, rather than of maternal tissues. In 392 part, this may be attributable to direct inhibition of fetal growth by corticosterone crossing the 393 placenta (Fowden et al., 1996) but may also be due to the decreased placental transport of 394 glucose, seen in this study, and of amino acids, observed previously (Vaughan et al., 2012) . 395
Oral corticosterone treatment did not alter liver glycogen content or G6pase activity, in 396 contrast to previous studies in pregnant animals using the synthetic glucocorticoid, 397 dexamethasone (Klepac, 1985; Franko et al., 2007) . Downregulation of both the 398 glucocorticoid receptor (Nr3c1) and the glucocorticoid-activating isoform of 11β-399 hydroxysteroid dehydrogenase (Hsd1) may mean that local corticosterone bioactivity was not 400 elevated sufficiently to alter liver enzyme expression, in the present study. Alternatively, the 401 net effect on hepatic carbohydrate metabolism may have been due to the balance of elevated 402 plasma corticosterone and increased insulin signalling. In contrast to the effect of 403 glucocorticoid treatment in the non-pregnant rat (Saad et al., 1993) , there was no 404 downregulation of hepatic IR or IGF1R expression here. Indeed, the phosphorylation state of 405 signalling proteins downstream of the insulin receptor broadly reflected a normal response to 406 elevated insulin. Both Akt and GSK-3β were hyperphosphorylated during corticosterone 407 treatment, which would be expected to suppress gluconeogenic enzyme expression. 408
Nonetheless, corticosterone treatment did increase hepatic Slc2a2 glucose transporter gene 409 expression on D16. Slc2a2 gene expression is linked to glucose availability in cultured 410 hepatocytes (Rencurel et al., 1996) and known to be transcriptionally regulated by other 411 hormones in vivo (Weinstein et al., 1994) . Whilst corticosterone treatment also tended to 412 decrease hepatic Slc2a1 expression, the transport capacity and absolute abundance of GLUT1 413 is low in the liver (Olson & Pessin, 1996) , meaning it is unlikely to influence glucose release. transporter expression in corticosterone treated mice (Vaughan et al., 2012) . In the present 477 study, placental glucose transport capacity was specifically reduced when maternal plasma 478 corticosterone concentration and placental Redd1 expression were raised in the ad libitum 479 fed, corticosterone treated mice. In pair-fed, corticosterone treated dams, when plasma 480 corticosterone and placental Redd1 expression were similar to controls, MeG clearance was 481 not decreased even though the alterations in maternal insulin signalling and feto-placental 482 growth suggested that these dams had received a physiologically effective dose of 483 corticosterone. Thus, placental Redd1 expression was closely related to both the prevailing 484 maternal corticosterone concentration and glucose transport across the placenta. 485
486
In contrast to the current findings, corticosterone reduces placental amino acid transport in 487 both ad libitum and pair fed dams (Vaughan et al., 2012) . Corticosterone, therefore, appears 488 to affect placental transport of glucose and amino acids by different mechanisms. Since the 489 ratio of phosphorylated to total 4E-BP1 and p70 S6 kinase abundance was reduced incorticosterone-treated placentae irrespective of food intake in the current study, placental 491
amino acid transport appears to be more directly related to inhibition of mTOR than placental 492 glucose transport. Certainly, 4E-BP1 and p70 S6 kinase hypophosphorylation is associated 493 with reduced amino acid transporter protein expression in the placentae of rat dams deprived 494 of protein during pregnancy (Rosario et al., 2011) . Collectively, these observations suggest 495 that corticosterone reduces placental glucose transport via Redd1 independently of mTOR 496 while it acts to lower placental amino acid transport by inhibition of mTOR dependent 497 translation or translocation of transporters to the cell membrane. Indeed, the placental 498 adaptation in signalling downstream of mTOR induced by corticosterone overexposure may 499 be indirect and mediated by the maternal hyperinsulinaemia observed in both the ad libitum 500 fed and pair-fed groups of dams. The precise effects of corticosterone on placental nutrient 501 transport, therefore, depend on both its actual circulating concentration and its longer term 502 actions on maternal metabolism and other metabolic hormone concentrations. Fetal sex may 503 also be an important factor in determining the effect of maternal corticosterone on materno-504 fetal nutrient transport, as the normal permeability of the placenta to natural glucocorticoids 505 is known to differ between male and female conceptuses (Montano et al., 1993) . 506 507 Overall, the data show that increased concentrations of natural glucocorticoids in the 508 pregnant mother may limit materno-fetal glucose partitioning and thus fetal growth by 509 reducing placental glucose transport capacity. Moreover, whilst natural glucocorticoids 510 increase insulin signalling and glucose transporter expression in the maternal liver, they 511 impair insulin signalling in the placenta with possible consequences for the activity of other 512 nutrient transport systems. As glucose is the major substrate of fetal growth and oxidative 513 metabolism, these effects are likely to impact upon the size and metabolic phenotype of the 514 infant at birth. However, the interaction of glucocorticoids with other nutrient sensing 515 pathways in the placenta may represent a target for interventions to rescue fetal growth when 516 maternal glucocorticoids are raised during pregnancy. 517 Body weight g 29.6 ± 0.5 27.8 ± 0.4* 34.6 ± 0. control n=7, corticosterone-treated n=5; D19 control n=17, corticosterone-treated ad libitum n=7, corticosterone-treated pair-fed n=5.
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Mean ± SEM placental expression of genes involved in glucose transport and glucocorticoid 
